VALENCIA, SPAIN--(NewMediaWire - Nov 17, 2016) - Zenosense,
Inc. (OTCQB:
ZENO) ("Zenosense", the "Company"), a healthcare technology
company primarily focused on the development and commercialization
of MIDS Cardiac™, a Point of Care ("POC") handheld device for the
early detection of certain cardiac event biomarkers to
significantly accelerate the triage, diagnosis, treatment and
disposition of patients reporting chest pain and with suspected
acute myocardial infarction (heart attack), is pleased to announce
that it has received an independent Proof of Market report from
MIDS Medical Limited ("MML"), our 40% owned joint venture based at
Sci-Tech, Daresbury, UK.
The comprehensive report focuses on the commercial potential for
MML's MIDS Cardiac development. MIDS Cardiac™ is intended to
perform high sensitivity troponin assays at the POC, using a
Magnetic Immunoassay Detection System ("MIDS technology"), an
intellectual property utilized under license and being further
developed by MML.
The report includes;
- Primary research consisting of in-depth expert interview and
analysis conducted by various methods including online and postal
questionnaires, telephone and face to face interviews.
Secondary research consisting of desk based analysis of specialist
publications, official statistics, government reports, industry
publications, technical and scientific journals, patent databases
and competitor websites.
Business case development and market exploitation plans devised
from an analysis of the secondary and primary research.
The report was originally paid for by Innovate UK, the UK
Government innovation agency, by a grant made to the developer and
owner of the MIDS technology in 2015, and updated in 2016 for MML
by the author Inventya Ltd with input from MML. The full report is
available on the following page at the Company's website
- https://www.zenosense.com/proof-of-market
About Zenosense, Inc.
Zenosense Inc.'s primary focus, through our joint venture
ownership in MIDS Medical Ltd., is the development of a
cost-effective, hand-held Point of Care rapid cardiac diagnostic
device, MIDS Cardiac™, and is also the holder of an exclusive
global license agreement to develop and market effective medical
devices for use in hospitals and primary healthcare settings
targeting the early detection of both deadly bacteria and certain
cancers in the exhaled breath of patients.
To find out more about Zenosense (OTCQB:
ZENO), visit our website at www.zenosense.com.
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking statements
can often be identified by words such as "expects," "intends,"
"plans," "may," "could," "should," "anticipates," "likely,"
"believes" and words of similar import. Forward-looking
statements are based on current facts and analyses and other
information that are based on forecasts of future results,
estimates of amounts not yet determined and assumptions of
management. Actual results may differ materially from those
expressed or implied by forward-looking statements due to a variety
of factors that may or may not be foreseeable or within the
reasonable control of the Company. Readers are cautioned not
to place undue reliance on such forward-looking
statements. Additional information on risks and other factors
that may affect the business and financial results of the Company
can be found in filings of the Company with the U.S. Securities and
Exchange Commission, including without limitation the section
entitled "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2015 filed on filed on May 23,
2016, and in Company reports filed subsequently
thereto. Except as otherwise required by law, the Company
disclaims any obligations or undertaking to publicly release any
updates or revisions to any forward-looking statement contained in
this news release to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.
Respective statements concerning the development of both MIDS
Cardiac™ and other devices under development have been made based
on information obtained from MIDS Medical Ltd. and Zenon Biosystem,
which the Company believes to be accurate, but have not been
independently verified.